the mice with double the muscle
1997 (myostatin discovery); Follistatin 344 identified as the potent isoform / used experimentally as a myostatin blocker from the early-to-mid 2000s
In 1997 a Johns Hopkins geneticist deleted a single gene from a mouse and it grew up looking like a cartoon bodybuilder — roughly double the muscle of its littermates — because that gene, which he named "myostatin," turned out to be the body's own brake pedal on muscle growth.
The story starts not with a bodybuilder but with a gene hunt: in the mid-1990s, Johns Hopkins geneticist Se-Jin Lee and postdoc Alexandra McPherron went fishing for unknown members of the TGF-beta protein family and reeled in a new gene they called GDF-8. When they bred mice lacking it, the animals grew up with roughly double the normal muscle mass — bulging haunches, broad shoulders, low body fat, no exercise or drugs required. Lee renamed the gene myostatin, because its absence revealed its job as the body's own brake pedal on muscle growth. Their 1997 paper in Nature made headlines worldwide, and the press nicknamed the animals 'mighty mice' — a label still turning up in the scientific literature nearly three decades later.
It turned out livestock breeders had been running the same experiment for two centuries without knowing it. British livestock writer George Culley documented the strange phenomenon of 'double muscling' in cattle back in 1807 — decades before the Belgian Blue breed even existed, since it was assembled by crossbreeding around the 1850s. Only in 1997, the same year as the mouse paper, did researchers find that Belgian Blue and Piedmontese cattle carry natural mutations in that very same myostatin gene, producing the exact double-muscled, low-fat build the lab mice had just shown off — proof the switch was real, conserved, and had already been selected for by farmers chasing meatier animals without knowing why it worked.
Then came the case that made it impossible to dismiss as an animal quirk. In 2004, a team led by Markus Schuelke at Berlin's Charite hospital reported in the New England Journal of Medicine — with Lee as a co-author — a newborn boy whose thigh and arm muscles bulged through his baby fat; by age four he could hold two 3-kilogram dumbbells straight out at arm's length. He carried two broken copies of the myostatin gene, and his mother, a former professional sprinter from a family famous locally for its strength, likely carried one. A splashier sequel followed in Liam Hoekstra, a Michigan toddler with myostatin-related muscle hypertrophy who reportedly held a gymnast's 'iron cross' at five months old and did pull-ups before his first birthday — inevitably dubbed 'Superbaby' by the press.
So where does follistatin come in? It was actually discovered first — isolated from ovarian fluid in 1987 — but once myostatin was characterized, researchers realized follistatin latches onto and neutralizes it too, acting as the body's own myostatin blocker. The '344' isn't marketing spin: Follistatin 344 is the 344-amino-acid version of the human protein, chosen for injection and gene therapy precisely because it circulates freely in the bloodstream rather than sticking to the tissue it's injected into. In 2007, Lee's own lab stacked a follistatin transgene on top of the myostatin knockout and produced mice with roughly quadruple the normal muscle mass — a sign follistatin releases more than one growth brake at once, not just the myostatin one.
The mouse, cattle, and human stories all hold up under independent sourcing — but one popular detail gets garbled: you'll often read that the Belgian Blue breed has been bred double-muscled since 1807. In truth, George Culley (a British livestock writer, not a naturalist) described double muscling in cattle generally in 1807, decades before the Belgian Blue breed itself was even created in the 1850s; the breed's natural myostatin mutation wasn't actually pinned down until 1997.
Despite the jaw-dropping mice and cattle, the human payoff has stayed frustratingly muted: myostatin-pathway drugs — antibodies like <b>bimagrumab</b> and follistatin gene therapy — have repeatedly underwhelmed in muscular-dystrophy and age-related muscle-loss trials, and none has won full approval. The strongest human signal remains <b>Jerry Mendell</b>'s AAV-delivered follistatin gene therapy for Becker muscular dystrophy, which reported improved walking distances in a 2015 trial — though a 2017 follistatin study in inclusion body myositis drew a published rebuttal accusing it of overstated claims. Meanwhile 'Follistatin 344' is sold unregulated online as a 'research peptide,' has sat on the <b>World Anti-Doping Agency</b>'s banned list since 2008, and independent testing of black-market vials has turned up inconsistent doses, contamination, and sometimes no follistatin at all.
